BVNK.F Stock Overview
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Bavarian Nordic A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.24.24 |
52 Week High | kr.32.05 |
52 Week Low | kr.17.45 |
Beta | 1.34 |
1 Month Change | -2.69% |
3 Month Change | -6.77% |
1 Year Change | -6.77% |
3 Year Change | -46.13% |
5 Year Change | 17.90% |
Change since IPO | -30.04% |
Recent News & Updates
Recent updates
Shareholder Returns
BVNK.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -0.06% | 2.1% |
1Y | -6.8% | 9.8% | 30.4% |
Return vs Industry: BVNK.F underperformed the US Biotechs industry which returned 9.8% over the past year.
Return vs Market: BVNK.F underperformed the US Market which returned 30.4% over the past year.
Price Volatility
BVNK.F volatility | |
---|---|
BVNK.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BVNK.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BVNK.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 1,379 | Paul Chaplin | https://www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
BVNK.F fundamental statistics | |
---|---|
Market cap | US$1.77b |
Earnings (TTM) | US$214.06m |
Revenue (TTM) | US$1.02b |
8.3x
P/E Ratio1.7x
P/S RatioIs BVNK.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BVNK.F income statement (TTM) | |
---|---|
Revenue | kr.7.06b |
Cost of Revenue | kr.1.90b |
Gross Profit | kr.5.16b |
Other Expenses | kr.3.69b |
Earnings | kr.1.48b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
Earnings per share (EPS) | 18.93 |
Gross Margin | 73.07% |
Net Profit Margin | 20.89% |
Debt/Equity Ratio | 0.2% |
How did BVNK.F perform over the long term?
See historical performance and comparison